Observational studyCancer reports (Hoboken, N.J.)2023

First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.

Christophe Le Tourneau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.